重组人血管内皮抑素联合恩沃利单抗一线治疗局部晚期肺腺癌的病例分析  

Case Analysis of Recombinant Human Vascular Endostatin Combined with Envafolimab for First-line Treatment of Locally Advanced Lung Adenocarcinoma

作　　者：张雪 冯青青 赵文飞 赵文文[2] 井文君 赵丽丽 魏红梅[2] ZHANG Xue;FENG Qingqing;ZHAO Wenfei;ZHAO Wenwen;JING Wenjun;ZHAO Lili;WEI Hongmei(Medical College of Qingdao University,Qingdao,Shandong 266000;Department of Oncology,Affiliated Qingdao Central Hospital of Qingdao University,Qingdao Cancer Hospital,Qingdao,Shandong 266000;Department of Oncology,Qingdao Traditional Chinese Medicine Hospital,Qingdao Hiser Hospital Affiliated to Qingdao University,Qingdao,Shandong 266042,China)

机构地区：[1]青岛大学医学部,山东青岛266000 [2]青岛大学附属青岛市中心医院,青岛市肿瘤医院肿瘤科,山东青岛266000 [3]青岛市中医医院(市海慈医院),青岛大学附属青岛市海慈医院肿瘤科,山东青岛266042

出　　处：《药学与临床研究》2023年第2期177-181,共5页Pharmaceutical and Clinical Research

摘　　要：本文报道了本院应用重组人血管内皮抑素联合恩沃利单抗成功治疗的1例肺腺癌患者的临床资料。该患者诊断为ⅢB期肺腺癌,无常见敏感基因突变,细胞程序性死亡-配体1(PD-L1)阴性,但TP53、ATM基因突变。有肺气肿、腹主动脉瘤等基础疾病,治疗依从性差,拒绝放化疗,一线予以重组人血管内皮抑素联合恩沃利单抗疗效及安全性好,无进展生存期达12月余。该病例报道提示抗肿瘤血管生成联合免疫检查点抑制剂具有协同作用,且重组人血管内皮抑素在有基础疾病的老年人中安全性好。TP53、ATM基因可能是指导抗免疫治疗的潜在预测因素。This paper reported the clinical data of a patient with lung adenocarcinoma successfully treated with recombinant human vascular endostatin combined with envafolimab.This patient was diagnosed with stageⅢB lung adenocarcinoma without common sensitive gene or PD-L1 mutations,but with TP53 and ATM gene mutations.The patient had basic diseases such as emphysema and abdominal aortic aneurysm,appeared poor treatment compliance and refused radiotherapy and chemotherapy.He received first-line treatment of endostatin combined with envafolimab and achieved good efficacy and safety,and a progression-free survival period of more than 12 months.This case suggests the synergistic effects of anti-tumor angiogenesis combined with immune checkpoint inhibitors and the good safety profile of recombinant human vascular endostatin in the elderly with underlying diseases.TP53,ATM gene may be potential predictors in guiding anti-immunotherapies.

关 键 词：非小细胞肺癌 抗血管生成 免疫检查点抑制剂 一线治疗 

分 类 号：R969.3[医药卫生—药理学] R734.2[医药卫生—药学]